(Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. (“Yerbae”) after ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

GN Store Nord A/S hereby announces that on May 22, 2025, pursuant to Section 38 (1) and Section 39 (1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million.

AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 ...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.

On January 29, 2025, Inventiva announced the publication in Journal of Hepatology of the results of the investigator-initiated proof-of-concept clinical trial led by Dr. Kenneth Cusi, demonstrating ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Jefferies is acting as lead book-running manager for the offering and H.C. Wainwright & Co. is acting as co-manager for the offering. Gyre intends to use the net proceeds from this offering, together ...